Cargando…

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma

INTRODUCTION: Medulloblastoma (MB) is the most frequent malignant brain tumor in children. Four subgroups with distinct genetic, epigenetic and clinical characteristics have been identified. Survival remains particularly poor in patients with Group 3 tumors harbouring a MYC amplification. We herein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ecker, Jonas, Oehme, Ina, Mazitschek, Ralph, Korshunov, Andrey, Kool, Marcel, Hielscher, Thomas, Kiss, Judit, Selt, Florian, Konrad, Carina, Lodrini, Marco, Deubzer, Hedwig E, von Deimling, Andreas, Kulozik, Andreas E, Pfister, Stefan M, Witt, Olaf, Milde, Till
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382927/ https://www.ncbi.nlm.nih.gov/pubmed/25853389 http://dx.doi.org/10.1186/s40478-015-0201-7

Ejemplares similares

EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA
por: Valinciute, Gintvile, et al.
Publicado: (2021)

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
por: Valinciute, Gintvile, et al.
Publicado: (2023)

Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
por: Vollmer, Johanna, et al.
Publicado: (2023)

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma
por: Schwalbe, Edward, et al.
Publicado: (2022)

Update on molecular and genetic alterations in adult medulloblastoma
por: Kool, Marcel, et al.
Publicado: (2012)

MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma
por: Lodrini, Marco, et al.
Publicado: (2013)

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts
por: Mynarek, Martin, et al.
Publicado: (2022)

EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM
por: Ecker, Jonas, et al.
Publicado: (2021)

MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS
por: Mynarek, Martin, et al.
Publicado: (2020)

Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses
por: Okonechnikov, Konstantin, et al.
Publicado: (2023)

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing
por: Selt, Florian, et al.
Publicado: (2016)

Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma
por: Krausert, Sonja, et al.
Publicado: (2022)

Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression
por: Korshunov, Andrey, et al.
Publicado: (2022)

MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN)
por: Ghasemi, David N, et al.
Publicado: (2020)

Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
por: Thole, Theresa M, et al.
Publicado: (2017)

LGG-16. NOVEL COMBINATION THERAPIES FOR PEDIATRIC LOW-GRADE GLIOMA AND CHARACTERIZATION OF THE UNDERLYING CELL DEATH MECHANISMS
por: Zeiser, Constantia, et al.
Publicado: (2023)

Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma
por: Tzaridis, Theophilos, et al.
Publicado: (2016)

Mitochondrial DNA mutations in Medulloblastoma
por: Funke, Viktoria L. E., et al.
Publicado: (2023)

Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma
por: Schwinn, Stefanie, et al.
Publicado: (2021)

Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells
por: Kawauchi, D, et al.
Publicado: (2017)

EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY
por: Delaidelli, Alberto, et al.
Publicado: (2021)

Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma
por: Chan, Tiffany S Y, et al.
Publicado: (2021)

LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2020)

PATH-03. Clinically Tractable Outcome Prediction of Group 3/4 Medulloblastoma Based on TPD52 Immunohistochemistry: a Multicohort Study
por: Delaidelli, Alberto, et al.
Publicado: (2022)

Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation
por: Rettig, I, et al.
Publicado: (2015)

MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation
por: Kolodziejczak, Anna, et al.
Publicado: (2022)

Epigenetic Silencing of DKK3 in Medulloblastoma
por: Valdora, Francesca, et al.
Publicado: (2013)

MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome
por: Kolodziejczak, Anna, et al.
Publicado: (2022)

Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis
por: Lacroix, Jeannine, et al.
Publicado: (2014)

Molecular subgroups of medulloblastoma: the current consensus
por: Taylor, Michael D., et al.
Publicado: (2011)

Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells
por: Robson, Jonathan P., et al.
Publicado: (2019)

Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept
por: Rieken, Stefan, et al.
Publicado: (2010)

Proof-of-Concept for Liquid Biopsy Disease Monitoring of MYC-Amplified Group 3 Medulloblastoma by Droplet Digital PCR
por: Stepien, Natalia, et al.
Publicado: (2023)

LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma
por: Sigaud, Romain, et al.
Publicado: (2022)

LGG-03. EXPLORING THE SIGNALING NETWORK INVOLVED IN MAPK PATHWAY INHIBITION BY THE MEK INHIBITOR TRAMETINIB IN BRAF-FUSION-DRIVEN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma
por: Kocher, Daniela, et al.
Publicado: (2022)

BIOL-10. DISTRIBUTION AND VULNERABILITY OF TRANSCRIPTIONAL OUTPUTS ACROSS THE GENOME IN MYC-AMPLIFIED MEDULLOBLASTOMA CELLS
por: Yang, Rui, et al.
Publicado: (2021)

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status
por: Gottlieb, Aline, et al.
Publicado: (2017)

Group-specific cellular metabolism in Medulloblastoma
por: Funke, Viktoria L. E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9hplavc5lafdmojiique4qfpqb